All In Biotech

Drug Trial Radar · NCT00061750

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis

Last checked: Nov 19, 2026Latest source record: Apr 19, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 595 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

595

Actual

Start

May 2003

Primary completion

Nov 2004

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 4, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is as effective and as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.

Conditions

  • Beta-Thalassemia

Interventions

  • ICL670Drug

  • deferoxamineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demonstrate non-inferiority to deferoxamine in its effects on liver iron content (LIC)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital of Los Angeles

    Los Angeles, California

  • Children's Hospital Oakland

    Oakland, California

  • Stanford Hospital

    Stanford, California

  • Children's Memorial Hospital

    Chicago, Illinois

  • Children's Hospital Boston

    Boston, Massachusetts

  • Weill Medical College of Cornell University

    New York, New York

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.